Phase II study of biweekly administration of docetaxel and irinotecan in patients with refractory or relapsed advanced non-small cell lung cancer

[1]  R. Spizzo,et al.  Phase II study of irinotecan and docetaxel in patients with previously treated non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 007). , 2006, Lung cancer.

[2]  A. Reissig,et al.  Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Renato Martins,et al.  Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.

[4]  T. Economopoulos,et al.  Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  E. Smit,et al.  A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb–IV non-small-cell lung cancer who failed first-line treatment , 2004, British Journal of Cancer.

[6]  K. Kiura,et al.  Phase I study of docetaxel and irinotecan in patients with advanced non-small-cell lung cancer. , 2004, Lung cancer.

[7]  M. Lázaro,et al.  Biweekly docetaxel as second-line chemotherapy of patients with advanced non-small cell lung cancer: a phase II study of the Galician Lung Cancer Group (GGCP 006-00) , 2004, Anti-cancer drugs.

[8]  Miklos Pless,et al.  Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Loddenkemper,et al.  Weekly docetaxel as second-line chemotherapy in advanced non-small cell lung cancer: phase II trial. , 2004, Anticancer research.

[10]  E. Esteban,et al.  Activity of weekly irinotecan (CPT-11) in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes , 2003, Investigational New Drugs.

[11]  R. Rosell,et al.  Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism , 2003, Investigational New Drugs.

[12]  R. Kanamaru,et al.  Biweekly administration regimen of docetaxel combined with CPT-11 in patients with inoperable or recurrent gastric cancer , 2003, Gastric Cancer.

[13]  R. Spizzo,et al.  P-29 Phase II study of irinotecan plus docetaxel in previously treated non-small cell lung cancer (NSCLC) patients: preliminary results. An Alpe Adria thoracic oncology multidisciplinary group study (ATOM 007) , 2003 .

[14]  A. Russo,et al.  Weekly docetaxel as II line therapy in non-small cell lung cancer: an interim analysis of a phase II study. , 2001, Lung cancer.

[15]  R. Lilenbaum,et al.  Phase II trial of weekly docetaxel in second‐line therapy for nonsmall cell lung carcinoma , 2001, Cancer.

[16]  M. Ducreux,et al.  Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Fukuoka,et al.  Phase I and pharmacologic study of docetaxel and irinotecan in advanced non-small-cell lung cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  J. Hainsworth,et al.  Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma , 2000, Cancer.

[19]  M. Kris,et al.  Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens , 2000 .

[20]  J. Dancey,et al.  Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Taron,et al.  Cytotoxic Effects of Topotecan Combined with Various Active G2/M-Phase Anticancer Drugs in Human Tumor-Derived Cell Lines , 2000, Investigational New Drugs.

[22]  J. Sloan,et al.  Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  K. Kiura,et al.  Establishment of a drug sensitivity panel using human lung cancer cell lines. , 1999, Acta medica Okayama.

[24]  J. Hainsworth,et al.  Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  S Lippman,et al.  Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Verweij,et al.  Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  M. Bissery,et al.  Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. , 1991, Cancer research.

[28]  I. Ringel,et al.  Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. , 1991, Journal of the National Cancer Institute.

[29]  T. Tanaka,et al.  Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors. , 1987, Cancer research.

[30]  R. Hertzberg,et al.  Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. , 1985, The Journal of biological chemistry.

[31]  L. Voltolini,et al.  Weekly low-dose docetaxel in advanced non-small cell lung cancer previously treated with two chemotherapy regimens. , 2003, Lung cancer.

[32]  D. Carbone,et al.  Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.